Want to see IN:KREBSBIO full AI Analyst Report?

Krebs Biochemicals & Industries Ltd. (KREBSBIO) Price & Analysis

0 Followers

KREBSBIO Stock Chart & Stats

₹71.00

-₹2.80(-2.89%)

At close: Jan 08 4:00 PM EST

₹71.00

-₹2.80(-2.89%)

Day’s Range― - ―

52-Week Range₹38.52 - ₹90.95

Previous CloseN/A

Volume3.29K

Average Volume (3M)726.00

Market Cap

₹1.42B

Enterprise Value₹3.65B

Total Cash (Recent Filing)₹1.27M

Total Debt (Recent Filing)₹2.19B

Price to Earnings (P/E)―

Beta1.51

Next Earnings

Aug 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-12.75

Shares Outstanding21,560,587

10 Day Avg. Volume346

30 Day Avg. Volume726

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)-0.53

Price to Sales (P/S)3.61

P/FCF Ratio-7.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Business Model DiversityKrebs sells both bulk drug APIs and specialty/industrial chemicals to B2B customers. This dual product mix provides structural revenue diversification across pharma and industrial end markets, helping absorb demand swings and enabling product‑mix shifts to protect long‑term sales resilience.

Industry Exposure (APIs & Specialty Chemicals)Operating in specialty/generic drug APIs and industrial chemicals ties the company to secular trends: pharmaceutical outsourcing and steady industrial chemical demand. These structural end‑market dynamics support persistent baseline demand beyond short‑term cycles, aiding long‑term revenue potential.

Gross Margin RecoveryGross margin turning positive in 2025–2026 signals improved cost control or a favorable product mix. If sustained, higher gross margins are a durable lever to restore operating profitability, improve cash flow prospects, and provide capacity to service debt or fund targeted capex.

Bears Say

Persistent Net LossesChronic operating and net losses materially erode retained capital and limit reinvestment. A very large recent net loss (~-71% margin) indicates deep profitability issues that require sustained operational turnarounds or external recapitalization to restore viability over the medium term.

Negative Shareholders' EquityConsistently negative equity and heavy leverage raise solvency and refinancing risk. Negative book equity restricts access to traditional funding, increases default vulnerability, and can force dilutive or costly recapitalizations, threatening the company's structural financial flexibility.

Consistent Cash BurnRepeated negative operating and free cash flow indicate ongoing cash burn that necessitates external funding for operations or debt service. Persistent FCF deficits constrain capex, R&D, and working capital, making long‑term turnaround dependent on reliable financing sources.

Krebs Biochemicals & Industries Ltd. News

Krebs Biochemicals Board Clears Q3 FY2025 Unaudited Results After Clean Review

Krebs Biochemicals & Industries Ltd. ( ($IN:KREBSBIO) ) has shared an update. Krebs Biochemicals & Industries Ltd. announced...

5M ago

Krebs Biochemicals to Shut Trading Window Ahead of Q3 Results

Krebs Biochemicals & Industries Ltd. ( ($IN:KREBSBIO) ) just unveiled an update. Krebs Biochemicals & Industries Ltd. has...

6M ago

KREBSBIO FAQ

What was Krebs Biochemicals & Industries Ltd.’s price range in the past 12 months?

Krebs Biochemicals & Industries Ltd. lowest stock price was ₹38.52 and its highest was ₹90.95 in the past 12 months.

What is Krebs Biochemicals & Industries Ltd.’s market cap?

Krebs Biochemicals & Industries Ltd.’s market cap is ₹1.42B.

When is Krebs Biochemicals & Industries Ltd.’s upcoming earnings report date?

Krebs Biochemicals & Industries Ltd.’s upcoming earnings report date is Aug 12, 2026 which is in 42 days.

How were Krebs Biochemicals & Industries Ltd.’s earnings last quarter?

Krebs Biochemicals & Industries Ltd. released its earnings results on May 21, 2026. The company reported -₹1.09 earnings per share for the quarter, missing the consensus estimate of N/A by -₹1.09.

Is Krebs Biochemicals & Industries Ltd. overvalued?

According to Wall Street analysts Krebs Biochemicals & Industries Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Krebs Biochemicals & Industries Ltd. pay dividends?

Krebs Biochemicals & Industries Ltd. does not currently pay dividends.

What is Krebs Biochemicals & Industries Ltd.’s EPS estimate?

Krebs Biochemicals & Industries Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Krebs Biochemicals & Industries Ltd. have?

Krebs Biochemicals & Industries Ltd. has 21,560,587 shares outstanding.

What happened to Krebs Biochemicals & Industries Ltd.’s price movement after its last earnings report?

Krebs Biochemicals & Industries Ltd. reported an EPS of -₹1.09 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.146%.

Which hedge fund is a major shareholder of Krebs Biochemicals & Industries Ltd.?

Currently, no hedge funds are holding shares in IN:KREBSBIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Krebs Biochemicals & Industries Ltd.

Established in 1991 and headquartered in Hyderabad, India, Krebs Biochemicals & Industries Limited primarily focuses on the production and distribution of active pharmaceutical ingredients (APIs) across India. The company also innovates by developing biotechnological processes applicable to the medical, agricultural, and industrial sectors. Its current portfolio includes compounds like androstenedione, lovastatin, and simvastatin, which serve as steroid intermediates and anti-cholesterol agents. Furthermore, Krebs Biochemicals is actively developing new products such as amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine, targeting diverse therapeutic applications including anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough relief. The firm also extends its expertise by offering contract manufacturing services to large pharmaceutical and multinational corporations.